Abstract
Monoamine transporters are the main targets of methamphetamine (METH). Recently, we showed that fluoxetine, a selective serotonin reuptake inhibitor (SSRI), decreased METH conditioned place preference (CPP), suggesting that serotonin transporter (SERT) inhibition reduces the rewarding effects of METH. To further test this hypothesis, in the present study we investigated the effects of additional SSRIs, paroxetine and fluvoxamine, on METH CPP in C57BL/6J mice. In the CPP test, pretreatment with 20 mg/kg paroxetine abolished the CPP for METH, whereas pretreatment with 100 mg/kg fluvoxamine prior to administration of METH failed to inhibit METH CPP. These results suggest that paroxetine, a medication widely used to treat depression, may be a useful tool for treating METH dependence. Further, these data suggest that molecules other than the SERT [such as G protein-activated inwardly rectifying K+ (GIRK) channels] whose activities are modulated by paroxetine and fluoxetine, but not by fluvoxamine, are involved in reducing METH CPP by paroxetine and fluoxetine.
Keywords: Conditioned place preference, Fluvoxamine, Methamphetamine, Mice, Paroxetine, Serotonin transporter, dopamine transporter, Knoutout mice, Biochemical Down Regulation
Current Neuropharmacology
Title: The Selective Serotonin Reuptake Inhibitor Paroxetine, but not Fluvoxamine, Decreases Methamphetamine Conditioned Place Preference in Mice
Volume: 9 Issue: 1
Author(s): Y. Takamatsu, H. Yamamoto, Y. Hagino, A. Markou and K. Ikeda
Affiliation:
Keywords: Conditioned place preference, Fluvoxamine, Methamphetamine, Mice, Paroxetine, Serotonin transporter, dopamine transporter, Knoutout mice, Biochemical Down Regulation
Abstract: Monoamine transporters are the main targets of methamphetamine (METH). Recently, we showed that fluoxetine, a selective serotonin reuptake inhibitor (SSRI), decreased METH conditioned place preference (CPP), suggesting that serotonin transporter (SERT) inhibition reduces the rewarding effects of METH. To further test this hypothesis, in the present study we investigated the effects of additional SSRIs, paroxetine and fluvoxamine, on METH CPP in C57BL/6J mice. In the CPP test, pretreatment with 20 mg/kg paroxetine abolished the CPP for METH, whereas pretreatment with 100 mg/kg fluvoxamine prior to administration of METH failed to inhibit METH CPP. These results suggest that paroxetine, a medication widely used to treat depression, may be a useful tool for treating METH dependence. Further, these data suggest that molecules other than the SERT [such as G protein-activated inwardly rectifying K+ (GIRK) channels] whose activities are modulated by paroxetine and fluoxetine, but not by fluvoxamine, are involved in reducing METH CPP by paroxetine and fluoxetine.
Export Options
About this article
Cite this article as:
Takamatsu Y., Yamamoto H., Hagino Y., Markou A. and Ikeda K., The Selective Serotonin Reuptake Inhibitor Paroxetine, but not Fluvoxamine, Decreases Methamphetamine Conditioned Place Preference in Mice, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795017236
DOI https://dx.doi.org/10.2174/157015911795017236 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Biochemical Strategies to Anticoagulation: A Comparative Overview
Current Vascular Pharmacology The Physiology of Nitric Oxide: Control and Consequences
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Cigarette Smoking in Methadone Maintained Patients: An Up-to-Date Review
Current Drug Abuse Reviews Connections Between Herpes Simplex Virus Type 1 and Alzheimer's Disease Pathogenesis
Current Alzheimer Research Is the Clinical Use of Cannabis by Oncology Patients Advisable?
Current Medicinal Chemistry Preparing for Pregnancy: A Body Weight Perspective and Update of the Literature
Current Nutrition & Food Science Structural Preferences of Neuroprotective S14G-Humanin Peptide Analyzed by Molecular Modeling and Circular Dichroism
Protein & Peptide Letters IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System
Current Drug Targets A Review on Pharmacological Properties of Coumarins
Mini-Reviews in Medicinal Chemistry Insight, Outcome and Recovery in Schizophrenia Spectrum Disorders: An Examination of their Paradoxical Relationship
Current Psychiatry Reviews Solution-Phase Parallel Synthesis of N-Arylisoquinuclidines
Letters in Drug Design & Discovery The Role of Continuous Positive Airway Pressure in the Treatment of Hypertension in Patients with Obstructive Sleep Apnea-Hypoapnea Syndrome: A Review of Randomized Trials
Reviews on Recent Clinical Trials Small Molecules in Stem Cell Research
Current Pharmaceutical Biotechnology Acute Ischemic Cerebrovascular Events on Antiplatelet Therapy: What is the Optimal Prevention Strategy?
Current Pharmaceutical Design Cytochrome P450 and the Biological Clock in Mammals
Current Drug Metabolism Microwave-Assisted Synthesis of Benzo-fused Seven-membered Azaheterocycles
Mini-Reviews in Organic Chemistry Rat Ultrasonic Vocalizations and Behavioral Neuropharmacology: From the Screening of Drugs to the Study of Disease
Current Neuropharmacology Recent Advances in Drug Repurposing for Parkinson’s Disease
Current Medicinal Chemistry Probiotics in the Prevention of Urogenital Tract Infections. Mechanisms Involved
Current Women`s Health Reviews Isolation and Characterisation of Acetylcholinesterase Inhibitors from Aquilaria subintegra for the Treatment of Alzheimer’s Disease (AD)
Current Alzheimer Research